Free Participation
Home Visits
Quality Research

FOR THOSE WITH ASTHMA-LIKE RAO OR SPAOPD,
EVERY BREATH CAN BE A STRUGGLE

If you know a horse with one of these diseases (which you may know as equine COPD or heaves) – you’ve seen how they can suffer. Inflammation of the airways causes breathlessness, wheezing, and coughing that no horse should experience

You may be one of the few who can help
If your horse is over age four and has been diagnosed with Recurrent Airway Obstruction (RAO) or Summer Pasture Associated Obstructive Pulmonary Disease (SPAOPD), your horse may be eligible to participate in this FDA-regulated clinical study of an investigational medication that will help bring much-needed quality research to the equine community.

Afflicted horses are now being recruited for this study to carefully evaluate an investigational drug with the potential to treat RAO and SPAOPD.

Our hope is that the research will result in an approved treatment – because today there are far too few FDA-approved drugs for horses afflicted with these diseases.

You can get full information on the study here, including which horses qualify, what’s involved, benefits to you, and how you can help.

Free Participation
Home Visits
Quality Research

The medication given to horses in the study may or may not help their condition. As with all medications, there are risks and benefits—all of which will be discussed with you prior to enrolling your horse.

© 2017 Visionaire Research and Education. All rights reserved.

Diagnosed horses are currently being sought.

Participation is free, as are all diagnostic tests and evaluations required for the study, and the study investigator will come to your location, so no travel is required. You will also earn credits to spend on goods and services at your referring veterinary clinic.

As with all medications, there are risks and benefits—all of which will be thoroughly discussed with you prior to enrolling your horse.

As an FDA-regulated study, the trial will comply with strict standards for quality, consistency, and statistical evaluation.

The goal of the study is to potentially provide a new FDA-approved alternative for safely treating these equine diseases.

    Is your horse eligible?
    Horses who meet the following criteria and who have had at least two RAO/SPAOPD episodes since age four may be considered for screening.

  • Diagnosed by your equine veterinarian as having RAO or SPAOPD
  • ≥ 200 kg (441 lbs.)
  • ≥ 4 years of age
  • Not pregnant or lactating
  • Not intended for breeding during the study period

What is involved?

How will the medication be administered?
You will be trained in how to administer the investigational mediction via a device in your horse’s left nostril. This quick video shows you how. (Participating owners are provided the password upon enrollment of their horses.)

What’s your first step?
Contact the investigator nearest you for information; there are 20 investigators in multiple cities across U.S. Use the zip code search function on the Find an investigator page to see if there’s one near you.

Free Participation
Home Visits
Quality Research

The medication given to horses in the study may or may not help their condition. As with all medications, there are risks and benefits—all of which will be discussed with you prior to enrolling your horse.

© 2017 Visionaire Research and Education. All rights reserved.

RECURRENT AIRWAY OBSTRUCTION (RAO)
SUMMER PASTURE ASSOCIATED OBSTRUCTIVE
PULMONARY DISEASE (SPAOPD)

When breath doesn’t come easily

RAO and SPAOPD are equine diseases similar to asthma in humans –which you may have heard referred to as COPD or heaves in horses. They are indistinguishable from one another except that SPAOPD horses develop symptoms while on pasture.

It is vital to have FDA-approved treatments for equine diseases like these, and only carefully conducted research studies can make these treatments available.

What causes RAO and SPAOPD?

RAO

RAO is caused by airborne molds, mites, bacterial endotoxins, inorganic compounds, and dust in the barn environment.

SPAOPD

SPAOPD, also known as the “summer heaves” is triggered by seasonal airborne antigens outdoors in a pasture environment.

Your horse’s signs may include:
  • Coughing
  • Mucopurulent nasal discharge
  • Nasal flaring
  • Expiratory wheezing
  • Abdominal breathing pattern at rest

If your horse has been diagnosed with one of these conditions and meets the study requirements, please contact a study investigator in your area. You are one of the few people who can help with this important research and possibly open the door to new treatments.

Free Participation
Home Visits
Quality Research

The medication given to horses in the study may or may not help their condition. As with all medications, there are risks and benefits—all of which will be discussed with you prior to enrolling your horse.

© 2017 Visionaire Research and Education. All rights reserved.

FREQUENTLY ASKED QUESTIONS

1. What are the requirements for participation in the study?
  • Domestic horses only (no mules, donkeys, zebras etc.)
  • ≥ 4 years of age
  • ≥ 200 kg (441 lbs.)
  • Veterinary diagnosis of RAO or SPAOPD
  • At least two RAO/SPAOPD episodes since age four
  • Not pregnant or lactating
  • Not intended for breeding during study

2. Why is this research important?
RAO and SPAOPD cause considerable suffering and diminished quality of life for affected horses, and today there are very few FDA-approved drugs for animals afflicted with these diseases. This research may result in an important new FDA-approved option for treatment, providing relief for horses all across the U.S.

3. Is this a high-quality clinical study?
The study is FDA-regulated, which ensures consistency, adherence to strict standards, and statistical evaluation of results. The study is placebo-controlled and double-blinded, which is considered the standard for quality clinical research.

4. Does it cost anything to participate?
Participation in the clinical study is free, as are all diagnostic tests and evaluations required for the study. The study investigator will come to your location.

5. Will I be compensated?
In addition to helping with vital research that may benefit horses for years to come, participating horse owners will earn credits that can be used for goods and services at their referring veterinary clinic after completion of the study.

6. How will the medication be administered?
The investigational medication is administered via a device in your horse’s left nostril. A password-protected how-to video which demonstrates how to administer the drug, is available for owners who have enrolled their horses.

7. How long will the study take?
Phase 1 of the study will take ten days. Phase 2, which will assess the medication’s safety in extended use, will run for 90 days.

8. What is the first step?
If your veterinarian has diagnosed RAO or SPAOPD in your horse, click this link to learn if there is a study investigator near you. You can also call or email us for more information. (See below.)

Free Participation
Home Visits
Quality Research

The medication given to horses in the study may or may not help their condition. As with all medications, there are risks and benefits—all of which will be discussed with you prior to enrolling your horse.

© 2017 Visionaire Research and Education. All rights reserved.

LEARN IF THERE IS A PARTICIPATING INVESTIGATOR
(EQUINE VETERINARIAN) NEAR YOU

For horses in the U.S. only.

      Free Participation
      Home Visits
      Quality Research

      The medication given to horses in the study may or may not help their condition. As with all medications, there are risks and benefits—all of which will be discussed with you prior to enrolling your horse.

      © 2017 Visionaire Research and Education. All rights reserved.

      FOUR REASONS YOU CAN BE CONFIDENT REFERRING PATIENTS FOR THIS RESEARCH

      Referral Form Payment Forms

      Veterinary referrals are the most important way we recruit eligible horses to participate in the REACH study, and we want practitioners to feel absolutely confident that the experience will be positive for your patients, your clients, and your practice.

      Below are four key things we want you know about this study and its benefits. If you have additional questions, feel free to call one of the investigator sites at any time.

      1. This FDA-approved study will advance the knowledge base of veterinary medicine
      The goal of this study in the United States is to evaluate a proprietary glucocorticoid investigational medication for the treatment of RAO and SPAOPD in horses. As you no doubt already know, approved equine medications are limited, and veterinarians sometimes turn to off-label alternatives. This research will possibly bring a new FDA-approved drug to equine medicine and if so, a new option you can prescribe with peace of mind.

      2. Your clients will benefit from participation
      We have made every effort to ensure participation is convenient for your clients and to minimize stress for participating horses. All aspects of the study are free for your clients, and in consideration for participation, your clients will earn credits to spend for future goods and services at your practice.

      There are two distinct phases of this clinical trial:

      PHASE 1 (safety and efficacy evaluation)

      Lasts 10 days. If the horse qualifies and the owner is interested in participating. Fifty percent of the equine patients in Phase 1 will receive the placebo.

      PHASE 2 (safety in extended use)

      Will last an additional 90 days. All horses will receive the investigational medication during phase 2.

      3. Your practice will benefit from referrals you make
      In addition to earning referral bonuses, referring veterinarians will benefit from the credit system we use to compensate participants. The clinic credit system is designed to ensure your client is rewarded and returns to your practice after the study is over and that your client relationship is maintained.

      4. You maintain your client relationships and control over future treatment
      Throughout the study, the investigator will be available to answer any questions (within confidentiality restrictions) you may have.

      When the study is over, the investigator can, if desired, work with you and your client to discuss options for further treatment using one of the medications already approved and available. All ongoing treatment decisions will be yours.

      We hope that you will keep this important study in mind as you work with your equine patients and colleagues.

      The inclusion criteria can be found here. Additional exclusion criteria is listed below which you may find helpful.

      CONDITION PARTICIPATION (YES/NO)
      Pregnant or Lactating No
      Currently Breeding No
      Systemic medication

      No intra-articular treatment with glucocorticoids within 14 days prior to inclusion.

      No systemic glucocorticoid (e.g. triamcinolone, methylprednisolone, betamethasone) within 6 weeks (42 days) prior to inclusion.

      No inhaled glucocorticoid (fluticasone, beclomethasone,) within 14 days prior to inclusion.

      No short-term glucocorticoids (dexamethasone, prednisolone, cortisone) within 14 days prior to inclusion.

      Bronchodilator No systemic bronchodilators (albuterol, clenbuterol, terbutaline) within 14 days prior to inclusion
      Other medications that exclude (within 14 days prior)

      No antibiotics

      No expectorants (guaifenesin, supplements)

      No mucolytic agents (acetylcysteine, nebulized saline)

      No other respiratory therapies (theophylline, antihistamines, omega-3 fatty acids)

      Change in environment No change in environment 14 days prior (bedding type, ventilation, amount of turn-out, feed)
      Participation in another study No participation in another study in the past 6 months or prior participation in this study
      Other health issues Generally okay as long as well-managed

      HAVE QUESTIONS ABOUT THE STUDY?
      CONTACT US.

      Call us Monday through Friday, 9 am to 5 pm Eastern time, or use the form below.

      Your Name (required)

      Your Email (required)

      Subject

      Your Message